**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/40, 31/44, 31/135, C07C 291/02, C07D 213/89 — A1

(11) International Publication Number: WO 97/39751

(43) International Publication Date: 30 October 1997 (30.10.97)

(21) International Application Number: PCT/US97/06604

(22) International Filing Date: 23 April 1997 (23.04.97)

(30) Priority Data:
60/016,276 23 April 1996 (23.04.96) US

(71) Applicant: CENTAUR PHARMACEUTICALS, INC. [US/US]; 484 Oakmead Parkway, Sunnyvale, CA 94086 (US).

(72) Inventors: NARDUCY, Kenneth, W.; 5621 Morningside Drive, San Jose, CA 95138 (US). DUZMAN, Efraim; 24 Starlight, Irvine, CA 92715 (US). CARNEY, John, Michael; 20010 Heritage Oak, Saratoga, CA 95070 (US). WILCOX, Allan, Lee; 784 Hans Avenue, Mountain View, CA 94040 (US).

(74) Agents: BENZ, William, H. et al.; Burns, Doane, Swecker & Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**
*With international search report.*
*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: COMPOSITIONS COMPRISING A NITRONE COMPOUND FOR USE IN TREATING OCULAR INFLAMMATION

(57) Abstract

Ophthalmic pharmaceutical compositions containing a pharmaceutically acceptable ophthalmic carrier and an inflammation-treating amount of a nitrone compound are disclosed. Also disclosed are methods for treating ocular inflammation conditions, such as uveitis, using pharmaceutical compositions.